Actively Recruiting

Phase 2
Phase 3
Age: 1Month - 2Months
All Genders
NCT05005897

Early Infant Micronutrition and Development

Led by Sykehuset Innlandet HF · Updated on 2023-04-18

600

Participants Needed

1

Research Sites

409 weeks

Total Duration

On this page

Sponsors

S

Sykehuset Innlandet HF

Lead Sponsor

U

University of Bergen

Collaborating Sponsor

AI-Summary

What this Trial Is About

Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. Poor status is also seen in affluent countries such as in Norway. Vitamin B12 is crucial for normal cell division and differentiation and necessary for the development and myelination of the central nervous system. Deficiency is also associated with impaired fetal and infant growth. In the proposed study we will measure the effect of daily oral vitamin B12 supplementation infants on neurodevelopment. We also aim to measure the impact of B12 supplementation on several other outcomes. Study design: Individually randomized double-blind placebo-controlled trial breastfed infants who will be assigned to a screening group (in which measurements will be obtained immediately) or a control group (in which serum will be stored and measurements done after one year). Pregnant women will be informed about the study during their first antenatal visit at the clinic and that we will re-approach them on their 6-week visit to their public health nurse. Infants who are deficient will be treated with peroral or intramuscular injections with 400 µg cyano-cobalamin. Infants in the control group will not be offered any intervention their blood sample will be stored for one year and then analyzed for the same nutrients as the intervention group. Outcomes: Primary: (i) neurodevelopment in children measured at 12 months of age (ii) growth in children measured by attained weight and length at 12 months. Secondary: (i) neurodevelopment and cognitive functioning in children later in life

CONDITIONS

Official Title

Early Infant Micronutrition and Development

Who Can Participate

Age: 1Month - 2Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Availability of informed verbal consent
  • Plan to reside in the defined study area for the next 12 months
  • Mothers intend to breastfeed their children for at least 8 months, and exclusively for 4 months
Not Eligible

You will not qualify if you...

  • Severe systemic illness requiring hospitalization
  • Growth retardation
  • Severe congenital malformations
  • Plasma cobalamin concentration below 148 pmol/L (these children will be treated for vitamin B12 deficiency and not included in the randomized trial but included in the cohort design)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Innlandet Hospital Trust

Lillehammer, Norway, 2615

Actively Recruiting

Loading map...

Research Team

C

Carolien Konijnenberg, Ph.D

CONTACT

K

Kjersti S Bakken, Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here